Effect of CKBM on Prostate Cancer Cell GrowthIn VitroandIn Vivo

Abstract

Prostate carcinoma and metastasis are common among male subjects worldwide. CKBM is a drug product targeting prostate cancer in multiple ways. Prostate cancer cell lines PC3 and DU145 were treated with CKBM. The effect of CKBM on the cell's viability, cell cycle, adhesive and invasive properties and its growth in an animal model were assessed. Results indicated that CKBM inhibited PC3 and DU145 cell growth in vitro at IC(50 )values 3.923 and 4.697% respectively, and it brought about cell cycle arrest at G2/M phase. CKBM also attenuated DU145 cells to invade and adhere to extracellular matrices including Matrigel, laminin, fibronectin and collagen IV. Moreover, PC3 tumor xenograft growth was inhibited by over 60% after 28-day of 0.2, 0.4 or 0.8 ml/day CKBM treatment. The present study indicates that CKBM is effective against prostate cancer cell growth in vitro and in vivo. Further studies are required to elucidate its mechanism of action.

Regression of prostate cancer xenografts by RLIP76 depletion

“…PTEN (phosphatase and tensin homolog), a protein known to inhibit Bcl-2 expression, caused reduction in the rate of growth of PC-3 xenografts; the combination of PTEN with radiation therapy (5 Gy) was more effective in slowing growth, but regression was not observed [33]. CKBM is a combination of herbs and yeasts, a drug product targeting prostate cancer, did cause delayed and incomplete regression by 28 days in xenografts of PC-3 prostate cell carcinoma, when treatment was started before established visible tumor was present [34]. Polyamine analogues containing cyclopropane rings caused reduction in the rate of growth of DU-145 prostate cancer xenografts, but regression was not observed [35].…”